The linked FDA records identify Novocure, GmbH as applicant on four device families filed under three PMA numbers. Optune Lua appears under P230042 with product code SDA for electrical tumor treatment fields for non-small cell lung cancer. Optune Pax appears under P250034 with product code SHC for a low electric field generator for pancreatic cancer treatment. Optune Gio and Optune HFE Transducer Arrays both appear under P100034 with product code NZK for a low electric field tumor treatment stimulator. The collection holds seven linked PMA records, three decided OK30 and four APPR, as of the snapshot date. [1][2][3]
Documented products and their filing scope
Optune Lua is described in its summary of safety and effectiveness data as tumor treatment fields, product code SDA, with an indication for adult patients with metastatic non-small cell lung cancer who have progressed on or after prior therapy, used concurrent with PD-1/PD-L1 inhibitors or docetaxel. The physician instructions for use repeat that indication and state that federal law restricts the device to sale by or on the order of a physician. Optune Pax is described as tumor treating fields, product code SHC, and its approval statement covers treatment of adult patients with locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel. [6][9][10]
Optune Gio and Optune HFE Transducer Arrays share PMA P100034 and product code NZK, a low electric field tumor treatment stimulator. The transducer arrays are named as a distinct trade name in the P100034 supplement record, indicating that array hardware is filed under the same PMA as the generator. [3][4]
Dated supplement activity
Three 30-day notices were decided in the snapshot: P230042/S010 for Optune Lua and P250034/S004 for Optune Pax, both decided October 26, 2026, and P100034/S046 for Optune HFE Transducer Arrays, decided September 16, 2026. Each is recorded as a process change involving manufacturer, sterilizer, packager or supplier. The Optune Lua and Optune Pax notices concern sterilization load configuration; the array notice concerns pallet configuration for gamma sterilization at Steris Schweiz. [1][2][4]
P100034/S045 for Optune Gio was approved September 18, 2026 under a normal 180-day track, covering a manufacturing site at SorVan Radiation, Ltd. in Yavne, Israel for sterilization. The original P250034 approval for Optune Pax was decided February 11, 2026, with a federal register notice date of February 20, 2026. [3][5]
Regulatory posture and what the records do not show
The Optune Pax summary states that the device was granted Breakthrough Device status on December 13, 2024, and that the applicant's manufacturing facility was inspected and found in compliance with the Quality System regulation in effect at the time. The Optune Lua summary carries the same compliance statement. These are FDA-authored statements about inspection status, not certifications held by the company. [6][9]
The seven linked records are a snapshot of supplied filings, not a measure of total portfolio, sales or safety performance. The sample of five records shows three OK30 and two APPR decisions; the full collection shows three OK30 and four APPR. No recall records appear in the supplied sample. Headquarters, ownership, website and commercial availability are not established by these filings, and the addresses appearing in FDA records are filing addresses. [1][5]
